Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics

Pacira BioSciences, Inc. (PCRX): $40.28

0.60 (+1.51%)

POWR Rating

Component Grades














  • Value is the dimension where PCRX ranks best; there it ranks ahead of 87.76% of US stocks.
  • PCRX's strongest trending metric is Value; it's been moving up over the last 178 days.
  • PCRX's current lowest rank is in the Sentiment metric (where it is better than 8.97% of US stocks).

PCRX Stock Summary

  • PCRX's current price/earnings ratio is 114.07, which is higher than 95.66% of US stocks with positive earnings.
  • With a year-over-year growth in debt of -32.37%, PACIRA BIOSCIENCES INC's debt growth rate surpasses just 9.1% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PCRX comes in at 22.13% -- higher than that of 92.02% of stocks in our set.
  • Stocks that are quantitatively similar to PCRX, based on their financial statements, market capitalization, and price volatility, are TWOU, OTRK, IAS, VRNT, and FUBO.
  • PCRX's SEC filings can be seen here. And to visit PACIRA BIOSCIENCES INC's official web site, go to

PCRX Valuation Summary

  • In comparison to the median Healthcare stock, PCRX's price/earnings ratio is 404.87% higher, now standing at 114.1.
  • Over the past 148 months, PCRX's price/sales ratio has gone down 5.4.

Below are key valuation metrics over time for PCRX.

Stock Date P/S P/B P/E EV/EBIT
PCRX 2023-03-17 2.7 2.3 114.1 46.4
PCRX 2023-03-16 2.9 2.5 119.8 48.1
PCRX 2023-03-15 2.7 2.3 113.7 46.3
PCRX 2023-03-14 2.7 2.3 113.2 46.2
PCRX 2023-03-13 2.7 2.3 111.5 45.7
PCRX 2023-03-10 2.8 2.4 115.7 46.9

PCRX Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 99.84%.
  • The 2 year net income to common stockholders growth rate now stands at 44796.51%.
  • Its 5 year net cashflow from operations growth rate is now at 100.19%.
Over the past 33 months, PCRX's revenue has gone up $233,036,000.

The table below shows PCRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 654.062 126.452 20.881
2022-06-30 614.318 144.085 39.234
2022-03-31 580.497 144.413 38.439
2021-12-31 541.533 125.717 41.98
2021-09-30 513.313 149.169 61.625
2021-06-30 503.075 128.663 174.084

PCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PCRX has a Quality Grade of C, ranking ahead of 72.8% of graded US stocks.
  • PCRX's asset turnover comes in at 0.394 -- ranking 116th of 681 Pharmaceutical Products stocks.
  • BCDA, NVAX, and RDHL are the stocks whose asset turnover ratios are most correlated with PCRX.

The table below shows PCRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.394 0.738 0.064
2021-03-31 0.381 0.731 0.042
2020-12-31 0.411 0.727 0.042
2020-09-30 0.451 0.729 0.029
2020-06-30 0.491 0.740 0.018
2020-03-31 0.536 0.749 0.030

PCRX Price Target

For more insight on analysts targets of PCRX, see our PCRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $79.00 Average Broker Recommendation 1.5 (Moderate Buy)

PCRX Stock Price Chart Interactive Chart >

Price chart for PCRX

PCRX Price/Volume Stats

Current price $40.28 52-week high $82.16
Prev. close $39.68 52-week low $35.35
Day low $39.82 Volume 350,700
Day high $40.99 Avg. volume 571,181
50-day MA $39.89 Dividend yield N/A
200-day MA $49.25 Market Cap 1.85B

Pacira BioSciences, Inc. (PCRX) Company Bio

Pacira Pharmaceuticals develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company was founded in 2006 and is based in Parsippany, New Jersey.

PCRX Latest News Stream

Event/Time News Detail
Loading, please wait...

PCRX Latest Social Stream

Loading social stream, please wait...

View Full PCRX Social Stream

Latest PCRX News From Around the Web

Below are the latest news stories about PACIRA BIOSCIENCES INC that investors may wish to consider to help them evaluate PCRX as an investment opportunity.

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Earnings Call Transcript

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good day and thank you for standing by. Welcome to the Quarter Four 2022 Pacira BioSciences, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be […]

Yahoo | March 9, 2023

Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference

TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 9:00 AM ET on Wednesday, March 15, 2023 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira BioSciences, Inc. (N

Yahoo | March 8, 2023

Q4 2022 Pacira Biosciences Inc Earnings Call

Q4 2022 Pacira Biosciences Inc Earnings Call

Yahoo | March 1, 2023

Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results

— Record revenues of $667 million in 2022 — — Full-year GAAP net income of $16 million and adjusted EBITDA of $213 million — — EXPAREL surpasses the 12 million patient mark — — Conference call today at 8:30 a.m. ET — TAMPA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2022. “2022 was a s

Yahoo | February 28, 2023

LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions

Multi-year agreement will make Pacira’s medical device ioveraº the Official Non-Opioid Pain Management Partner of the LPGADAYTONA BEACH, Fla. and TAMPA, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), a company committed to non-opioid pain management and regenerative health solutions, and the Ladies Professional Golf Association (LPGA) announced today a multi-year sponsorship that makes Pacira’s iovera° — a handheld medical device that provides non-medicated pai

Yahoo | February 23, 2023

Read More 'PCRX' Stories Here

PCRX Price Returns

1-mo N/A
3-mo 1.38%
6-mo -23.80%
1-year -46.56%
3-year 28.16%
5-year 24.71%
YTD 4.33%
2022 -35.83%
2021 0.55%
2020 32.10%
2019 5.30%
2018 -5.76%

Continue Researching PCRX

Want to see what other sources are saying about Pacira BioSciences Inc's financials and stock price? Try the links below:

Pacira BioSciences Inc (PCRX) Stock Price | Nasdaq
Pacira BioSciences Inc (PCRX) Stock Quote, History and News - Yahoo Finance
Pacira BioSciences Inc (PCRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8832 seconds.